Search Videos and More
Document
ASH 2021 Featured Oral Presentations
The Annual Meeting of the American Society of Hematology (ASH) will take place December 11-14th. To keep-up with latest advances, the live schedule of oral presentations by Dana-Farber faculty is attached for your convenience.
News
Discovery May Lead to Expanded Donor Pool for Stem Cell Transplants for Patients with Cancer
Researchers find that in many cases people with a condition known as clonal hematopoiesis can safely serve as stem cell transplant donors.
News
Finding New Targets for Acute Myeloid Leukemia in Children
Looking for genes AML needs for everyday survival turned up two strong ‘hits’ to pursue for therapeutic development.
News
Study Results Support Stem Cell Transplantation for Older Patients with Myelodysplastic Syndromes
Although stem cell transplantation is the only current therapy with the potential to cure myelodysplastic syndromes (MDS), it is rarely used as an initial treatment for older patients because it hasn’t been proven superior to other therapies. New research by Dana-Farber Cancer Institute investigators stands to overturn that practice.
Document
Mantle Cell Lymphoma Clinical Trial
Targeted combination therapy for mantle cell lymphoma with minimal residual disease assessment.
Video
Clinical Trial Spotlight: Venetoclax plus Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL)
Dr. Marlise Luskin, a specialist in the Adult Leukemia Program at Dana-Farber Cancer Institute, explains an innovative trial that combines the BCL2 inhibitor, venetoclax with chemotherapy for older patients with ALL.
Video
Stem Cell Transplant Beneficial for Older Patients with Myelodysplastic Syndrome
New research shows stem cell transplant represents the best therapeutic approach for older individuals with myelodysplastic syndrome. Dana-Farber Cancer Institute's Corey Cutler, MD, MPH, FRCPC explains more.
Video
Treatment for Adults with Acute Lymphoblastic Leukemia
Marlise Luskin, MD, MSCE, a leukemia specialist at Dana-Farber Cancer Institute describes treatment for adults with acute lymphoblastic leukemia (ALL). She explains treatment considerations for younger adults and older adults with ALL.
News
Triplet Therapy Shows Promise in Phase 2 Study in Chronic Lymphocytic Leukemia
Dana-Farber researchers find that combining a BCL-2 inhibitor with two other targeted agents is active in previously untreated CLL patients.
Podcast
FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
Dr. Munshi discusses the significance of the FDA approval of ide-cel in relapsed/refractory multiple myeloma, data from the KarMMa trial, which served as the basis for the approval, and next steps for CAR T-cell therapy in the field.
News
Hematologic Malignancies CME
The care of patients with hematologic malignancies is evolving rapidly. These video highlights will discuss new developments in the diagnosis and treatment of hematologic malignancies, as presented at the 2020 Annual Meeting of the American Society of Hematology (ASH).
News
Researchers Focus on How to Invigorate ‘Exhausted’ T-Cells in Immunotherapy
Despite the sometimes-dramatic success of new cancer immunotherapies like checkpoint inhibitor drugs and CAR T cells, thus far only a minority of patients have responded or gained long-lasting benefits.